Biosimilars at CinnaGen
Precision science applied at scale
Biosimilars at CinnaGen
Biosimilars are among the most demanding forms of biologic development. They require more than the ability to produce a molecule, they require the ability to demonstrate, with evidence, that a complex biologic behaves the same way as its reference medicine.
At CinnaGen, biosimilars are developed through a disciplined, science-driven process that integrates molecular characterization, analytical comparability, process control, and clinical validation. We approach biosimilar development not as a shortened pathway, but as one of the most rigorous applications of biologic science.
Because similarity must be proven, not assumed.
Technology Development Capabilities
Full-cycle development, designed for manufacturing reality
Technology Development Capabilities
What this enables
By integrating product science, process engineering, analytical control, and clinical execution, CinnaGen reduces development uncertainty and strengthens the ability to scale complex biologics, from early-stage development through commercial manufacturing.
This is how we build therapies that perform consistently, meet global standards, and support long-term access for patients.
Proven relevance in modern biologics
Many of the world's most widely used biologic therapies are complex molecules that require advanced manufacturing and analytical capabilities.
Today, CinnaGen develops and manufactures biosimilars corresponding to a significant share of the top-selling biologic medicines globally, reflecting both the scientific scope of our platform and the maturity of our development and production systems.
This focus positions CinnaGen to contribute meaningfully to expanding access to high-impact biologic therapies, without compromising clinical expectations.
This integration enables precise control of molecule behavior at all stages of development and production, allowing us to align with the world's most advanced biopharmaceutical platforms and enter the field of biological drug production and development. In this framework, biosimilar development is defined as one of the most complex and sensitive pathways of biological drug development; a pathway where even minor changes in structure, process, or production conditions can affect the final quality. For this reason, analytical precision, precise process design, and deep understanding of molecule dynamics play a decisive role. Today, the result of this scientific and infrastructural approach is visible in CinnaGen's product portfolio.
60% of the world's most important biological drugs are in CinnaGen's portfolio.
A sign of our scientific and infrastructural capability with the world's most advanced biopharmaceutical technologies.
